Previous 10 | Next 10 |
Global Blood Therapeutics ([[GBT]]) Q3 results:Revenues: $36.9M, resulting from sales of Oxbryta, driven by underlying patient demand, as well as good payer coverage.Q3 results compares to $31.5M in Q2, and represents a $4.8M or 17% sequential increase.The company recorded more than 1,000 new...
Global Blood Therapeutics, Inc. (GBT) Q3 2020 Earnings Conference Call November 5, 2020 4:30 p.m. ET Company Participants Steven Immergut - Head of Communications and IR Ted Love - President and CEO Jeff Farrow - CFO David Johnson - Chief Commercial Officer Conference Call Participants Alethi...
Gainers: [[FTSI]] +80%. [[AVNW]] +17.5%. [[AGS]] +16%. [[GLUU]] +15.8%. [[CNDT]] +9.2%.Losers: [[ASMB]] -38.6%. [[GBT]] -30.4%. [[AAOI]] -20.7%. [[MRIN]] -14%. [[NVRO]] -10%. For further details see: GLUU, AAOI, CNDT and GBT among after-hours movers
Global Blood Therapeutics (GBT): Q3 GAAP EPS of -$0.97 misses by $0.25.Revenue of $36.9M misses by $7.66M.Shares -22.2%.Press Release For further details see: Global Blood Therapeutics EPS misses by $0.25, misses on revenue
Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months ...
[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...
Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.69 (+35.5% Y/Y) and the consensus Revenue Estimate is $44.56MOver the last 1 year, GBT has beaten EPS estimates 25% of the time a...
Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting Long-Term Use of Oxbryta ® ( voxelotor ) Preclinical Data Highlights Promise of GBT ’ s S ickle C ell D isease Pipeline G...
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after U.S. financial markets close. Management will host a co...
Real-world effectiveness data on Oxbryta ® (voxelotor) in the treatment of sickle cell disease featured as oral presentation SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), today announced its parti...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...